Burkina Faso bans unapproved dengue treatment
Faso FDA orders immediate removal of 'DENGUE- med' from sale due to lack of authorization and safety evaluation.
The Faso Food and Drug Administration (Faso FDA) has prohibited the sale and use of a product called 'DENGUE- med', marketed as a dengue treatment. The announcement on November 6, 2026, stated that the product currently circulating in Burkina Faso lacks market authorization and has not undergone any quality, efficacy, or safety assessments by a competent authority.
Health professionals and pharmacies must immediately remove 'DENGUE- med' from shelves, quarantine existing stock, and report quantities and supplier details to Faso FDA. Prescribers are asked to report any adverse effects observed in patients using the product, as inspection teams will recover affected stock and enforce administrative and criminal sanctions for non-compliance.
The public is advised not to purchase or use 'DENGUE- med'. For symptoms like fever, headache, or joint pain, individuals should seek care at a health center. The Faso FDA also warned against using aspirin and anti-inflammatories like ibuprofen for suspected dengue due to increased bleeding risks.
Why it mattersThe Faso FDA banned the sale and use of the unapproved 'DENGUE- med' product, impacting public health and patient treatment.